Page 44 - ATHM26_4

CONCLUSIONS 19. Sirchia G, Rebulla P, Parravicini A, Carnelli V, Gianotti GA, Bertolini F. Leukocyte
depletion of red cell units at the bedside by transfusion through a new filter.
The current study clearly showed that LCAP therapy can Transfusion. 1987; 27:402-5.
significantly decrease RA disease activity. Furthermore, it 20. Anderson J, Caplan L, Yazdany J et al. Rheumatoid Arthritis Disease Activity
Measures: American College of Rheumatology Recommendations for Use in
showed that the therapy resulted in a reduction of serum Clinical Practice. Arthritis Care Res. 2012 May ;64(5):640-7.
levels of CXCL16 and serotonin, offering a putative 21. Prevoo ML, Van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van
mechanism by which the articular symptoms of RA were Riel PL. Modified disease activity scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal study of patients with
improved. rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48.
22. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in
arthritis. Arthritis Rheum. 1980 Feb;23(2):137-45.
ACKNOWLEDGMENTS 23. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.
This work is partly supported by grants from the Capital Health Research and American College of Rheumatology preliminary definition of improvement in
Development of Special (No.2014-1-4051). rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
24. Pincus T, Stein CM. ACR 20: clinical or statistical significance? Arthritis Rheum
AUTHOR’S DISCLOSURE STATEMENT 1999;42:1572–6.
The authors indicate that they have no conflicts of interest related to this study. 25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey
LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism
REFERENCES Association 1987 revised criteria for the classification of rheumatoid arthritis.
1. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Arthritis Rheum 31(3):315–324
Immunity. 2017; 46:183-96. 26. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM, de Vernejoul MC. The
2. Hahn G, Stuhlmuller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR. serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and
Modulation of monocyte activation in patients with rheumatoid arthritis by proliferation. FASEB journal : official publication of the Federation of American
leukapheresis therapy. The Journal of clinical investigation. 1993; 91:862-70. Societies for Experimental Biology. 2008; 22:418-27.
3. Kitagaichi M, Kusaoi M, Tsukahara T, Murayama G, Nemoto T, Sekiya F, et al. 27. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, et al.
Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with Oxidative stress by monoamine oxidase mediates receptor-independent
rheumatoid arthritis. Transfusion and apheresis science : official journal of the cardiomyocyte apoptosis by serotonin and postischemic myocardial injury.
World Apheresis Association : official journal of the European Society for Circulation. 2005; 112:3297-305.
Haemapheresis. 2016; 55:225-32. 28. Dray A. Inflammatory mediators of pain. Br J Anaesth 1995; 75:125-31.
4. Sakai Y, Sakai S, Otsuka T, Ohno D, Murasawa T, Munakata K, et al. Efficacy of 29. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost.
high-throughput leukocytapheresis for rheumatoid arthritis with a reduced 2011; 105:S13-33.
response to infliximab. Therapeutic apheresis and dialysis : official peer-reviewed 30. Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as
journal of the International Society for Apheresis, the Japanese Society for Apheresis, regulators of inflammation: novel players of cellular crosstalk in the rheumatic
the Japanese Society for Dialysis Therapy. 2009; 13:179-85. diseases. Arthritis and rheumatism. 2005; 52:3337-48.
5. Ueki Y, Sagawa A, Tanimura K, Yamada A, Yamamoto K, Tsuda H, et al. A 31. Gasser O, Schifferli JA. Microparticles released by human neutrophils adhere to
multicenter study of leukocytapheresis in rheumatoid arthritis. Clinical and erythrocytes in the presence of complement. Experimental cell research. 2005;
experimental rheumatology. 2007; 25:810-6. 307:381-7.
6. Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, 32. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ.
Ishizuka T, et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a Membrane-derived microvesicles: important and underappreciated mediators of
randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. cell-to-cell communication. Leukemia. 2006; 20:1487-95.
1999; 42:431-7. 33. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane
7. Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, et al. microparticles from circulating and vascular cells in regulating vascular function.
Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis- Am J Physiol Heart CircPhysiol. 2005; 288:1004-9.
-results of a randomized pilot trial. Digestive diseases and sciences. 2007; 52:2044- 34. Umekita K, Hidaka T, Ueno S, Takajo I, Kai Y, Nagatomo Y, et al. Leukocytapheresis
53. (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases
8. Ueki Y, Yamasaki S, Kanamoto Y, Kawazu T, Yano M, Matsumoto K, et al. the level of granulocytes-derived MPs: a possible connection with the effect of
Evaluation of filtration leucocytapheresis for use in the treatment of patients with LCAP on rheumatoid arthritis. Modern rheumatology. 2009; 19:265-72.
rheumatoid arthritis. Rheumatology. 2000; 39:165-71. 35. Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, et al.
9. Eguchi K, Saito K, Kondo M, Hidaka T, Ueki Y, Tanaka Y, et al. Enhanced effect of Activated platelets as a possible early marker to predict clinical efficacy of
high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Modern leukocytapheresis in severe ulcerative colitis patients. Journal of gastroenterology.
rheumatology. 2007; 17:481-5. 2006; 41:524-32.
10. Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, et al. 36. Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, et al. Modulation
Dynamic changes in cytokine levels in serum and synovial fluid following of platelet aggregation responses by leukocytapheresis therapy in patients with
filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Journal active ulcerative colitis. Journal of gastroenterology. 2006; 41:540-6.
of clinical apheresis. 2001; 16:74-81.
11. Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, et al.
Granulocytapheresis in the treatment of patients with rheumatoid arthritis.
Artificial organs. 1997; 21:989-94.
12. Fujimori J, Yoshino S, Koiwa M, Hirai H, Shiga H, Hayama N, et al. Improvement
in rheumatoid arthritis following application of an extracorporeal granulotrap
column, G-1. Rheumatology international. 1996; 15:175-80.
13. Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context
of rheumatoid arthritis. Nature reviews Rheumatology. 2016; 12:472-85.
14. Nanki T. Treatment for rheumatoid arthritis by chemokine blockade. Nihon
Rinsho Men’eki Gakkai kaishi = Japanese journal of clinical immunology. 2016;
39:172-80.
15. Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N.
Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis
and rheumatism. 2005; 52:3004-14.
16. van der Voort R, van Lieshout AW, Toonen LW, Sloetjes AW, van den Berg WB,
Figdor CG, et al. Elevated CXCL16 expression by synovial macrophages recruits
memory T cells into rheumatoid joints. Arthritis and rheumatism. 2005; 52:1381-
91.
17. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody
treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.
Rheumatology international. 2007; 27:467-72.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis and rheumatism. 1988; 31:315-24.

42 ALTERNATIVE THERAPIES, JUL/AUG 2020 VOL. 26 NO. 4 Huang—Leukocytapheresis Therapy for Rheumatoid Arthritis